peterschreiber.media Leerink has upgraded Ionis ( NASDAQ: IONS ) to outperform, citing the company’s drug candidate ION582 for Angelman syndrome, or AS. The investment firm said it sees “further upward pressure on estimates as AS value flows into models.
” Leerink also sees an even market split for ION582 and Ultragenyx's ( RARE ) GTX-102 with low double-digit percentage peak penetration for each asset “in a meaningful orphan market for which value is only beginning to be incorporated into IONS shares.” Leerink has a price target for the stock of $62. More on Ionis Pharmaceuticals Ionis Pharmaceuticals, Inc.
(IONS) HALOS Study of ION582 in Angelman Syndrome - (Transcript) Ionis: Tough Run For Share Price Belies Multiple Reasons For Optimism Ionis Pharmaceuticals, Inc. (IONS) Q1 2024 Earnings Call Transcript Ionis reports positive Phase 1/2 data for Angelman therapy Ionis gains as anti-lipid therapy undergoes FDA priority review.
